Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06025747 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Mar 3, 2027 → Aug 3, 2027
See other at-risk trials from University of Washington

Record History

  1. Primary completion pushed from Mar 3, 2027 to Aug 3, 2027 Completion moved earlier from Mar 3, 2029 to Mar 3, 2028 · Site details revised · Eligibility criteria shortened, about 2 words Show 3 more changesShow less
    • Completion moved earlier from Mar 3, 2029 to Mar 3, 2028
    • Site details revised
    • Eligibility criteria shortened, about 2 words
  2. Study title shortened, about 2 wordsv20 See this version in full on ClinicalTrials.gov ↗
  3. 2 versions Re-verified since Mar 25, 2026, no change to tracked fieldsv18-v19
  4. Lead sponsor: Fred Hutchinson Cancer Center to University of Washingtonv17
  5. Site contact updatedv16
Show 14 earlier versionsHide 14 earlier versions
  1. Re-verified, no change to tracked fieldsv15
  2. Start date changed from estimate of Apr 3, 2025 to Mar 19, 2025v14
  3. Primary completion date: Mar 3, 2025 to Mar 3, 2027 Start date: Feb 9, 2025 to Apr 3, 2025 · Completion date: Mar 3, 2026 to Mar 3, 2029v13 Show 2 more changesShow less
    • Start date: Feb 9, 2025 to Apr 3, 2025
    • Completion date: Mar 3, 2026 to Mar 3, 2029
  4. Lead sponsor: University of Washington to Fred Hutchinson Cancer Center Start date: Dec 26, 2024 to Feb 9, 2025 · Eligibility criteria expanded, about 16 words · Site contact updatedv12 Show 3 more changesShow less
    • Start date: Dec 26, 2024 to Feb 9, 2025
    • Eligibility criteria expanded, about 16 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  5. Start date: Nov 21, 2024 to Dec 26, 2024v11
  6. Start date: Oct 15, 2024 to Nov 21, 2024v10
  7. Start date: Sep 15, 2024 to Oct 15, 2024v9
  8. Trial status: Not Yet Recruiting to Recruiting Site details revisedv8 Show 1 more changeShow less
    • Site details revised
  9. Start date: Aug 8, 2024 to Sep 15, 2024v7
  10. Re-verified, no change to tracked fieldsv6
  11. Start date: Jul 1, 2024 to Aug 8, 2024v5
  12. Re-verified, no change to tracked fieldsv4
  13. Start date: Apr 1, 2024 to Jul 1, 2024v3
  14. Start date: Jan 1, 2024 to Apr 1, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial tests the safety, side effects, and best dose of abemaciclib and how well it works with radiation therapy before surgery in treating patients with high-risk adipocytic retroperitoneal sarcoma. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving abemaciclib together with radiation therapy before surgery may shrink tumors in patients with high-risk adipocytic retroperitoneal sarcoma.
Trial Details
NCT Number NCT06025747
Lead Sponsor University of Washington
Collaborators: Eli Lilly and Company
Conditions Retroperitoneal Sarcoma, Liposarcoma, Dedifferentiated Liposarcoma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov